Abstract: The present disclosure relates to a fusion protein of relaxin or an analogue and the medical use thereof. Specifically, the present disclosure relates to a fusion protein comprising relaxin or an analogue thereof and a serum albumin binding domain, and the medical use thereof for treating diseases (for example, heart failure). Moreover, the present disclosure relates to a serum albumin binding molecule, which comprises an immunoglobulin single variable domain (for example, VHH) capable of binding to serum albumin, has good plasma stability, and can be used for prolonging the plasma half-life of a drug.

Abstract: A human insulin analogue, and a fusion protein thereof and the medical use thereof. The human insulin analogue-Fc fusion protein has ultra-long in-vivo pharmacokinetic properties and can be used for treating metabolic diseases (such as type-I diabetes and type-II diabetes).

Abstract: Provided are an anti-FXI/FXIa antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof, as well as a pharmaceutical composition comprising the anti-FXI/FXIa antibody or the antigen-binding fragment thereof, and a method for treating and preventing a disease, in particular a method for treating thrombosis or thromboembolism-related diseases or disorders.